Financing ·
Dermata Therapeutics, Inc. entered into a private placement on August 16, 2026, raising approximately $3.4 million in…
DRMAWDermata Therapeutics, Inc.
Dermata Therapeutics, Inc. entered into a private placement on August 16, 2026, raising approximately $3.4 million in gross proceeds and an estimated $3.2 million net of expenses. The company issued 933,064 shares of common stock and pre-funded warrants for 1,360,544 additional shares at $1.46 per share to institutional investors, alongside Series E and F warrants exercisable at $1.46 per share. Company insiders contributed approximately $2.4 million at a slightly higher price of $1.47 per unit. Proceeds will fund general corporate purposes, including the launch of a new OTC acne kit on August 25, 2026, and potential acquisitions. The company operates in the dermatologic solutions industry, focusing on direct-to-consumer skincare products.